Virtus Investment Advisers’s Corvus Pharmaceuticals CRVS Stock Holding History

Virtus Investment Advisers’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$410K	Sell	27,427 -5,152	-16%	-$71.5K	0.1%	261
2026 Q1	$477K	Buy	32,579 +796	+3%	+$12.7K	0.13%	224
2025 Q4	$245K	Buy	31,783 +4,946	+18%	+$39K	0.07%	339
2025 Q3	$198K	Buy	26,837 +4,660	+21%	+$23.9K	0.06%	256
2025 Q2	$88.7K	Buy	22,177 +1,862	+9%	+$6.78K	0.03%	388
2025 Q1	$64.6K	Buy	+20,315	New	+$95.7K	0.02%	460

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Virtus Investment Advisers's CRVS Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Corvus Pharmaceuticals (CRVS) stake by 16% in Q2 2026, selling an estimated $71.5K and leaving 27,427 shares worth $410K. The position accounts for 0.1% of the portfolio, ranked #261.

Virtus Investment Advisers first reported a position in CRVS in Q1 2025 and has held it in 6 quarters since. The position peaked at $477K in Q1 2026. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Virtus Investment Advisers held 27,427 shares of Corvus Pharmaceuticals worth $410K as of Q2 2026.
Virtus Investment Advisers sold 5,152 Corvus Pharmaceuticals shares in Q2 2026, an estimated $71.5K.
Corvus Pharmaceuticals made up 0.1% of Virtus Investment Advisers's portfolio in Q2 2026, its #261 holding.
Virtus Investment Advisers first reported a position in Corvus Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Virtus Investment Advisers's Corvus Pharmaceuticals position peaked at $477K in Q1 2026.
173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.